They represent the point where cardiovascular risk becomes clinically significant
It also is not indicated for use in people with type 1 diabetes
The most commonly reported side effects in clinical trials include: Nausea Vomiting Diarrhea Constipation Most of these symptoms were mild to moderate and tended to improve over time as the body adjusted to the medication, especially when doses were increased gradually
While platforms like Brello standardize medication assignment based on BMI and comorbidity profiles, individuals may have underlying peptide pathway variants that influence how their bodies respond to semaglutide, tirzepatide, or other GLP-1 agonists
What dietary changes can help manage acid reflux on semaglutide
Although recent reviews have described the role of GLP-1 RAs on cardiovascular risk in general, there is a lack of evidence synthesis on local actions of GLP-1 RAs in coronary arteries and the link of these mechanisms to coronary events ((Figure 1)